KSE - Delayed Quote KRW

Hanall Biopharma Co., Ltd. (009420.KS)

27,400.00

+800.00

+(3.01%)

At close: 3:30:23 PM GMT+9

HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced that Batoclimab, an anti-FcRn treatment being developed for a range of autoimmune diseases, has received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and Welfare (MHLW) in Japan for active Thyroid Eye Disease (TED).

PR Newswire 25 days ago

009420.KQ

009420.KS
+3.01%
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals successfully completed their Phase 1 study of HL192 (ATH-399A), which is being developed as a disease-modifying therapy for Parkinson's disease. The study met its primary endpoints of safety and tolerability in 5 different ascending dose groups, demonstrating significant progress in the treatment of this debilitating neurological disorder. This first-in-human study included single ascending dose (SAD), multiple ascending dose (

PR Newswire 4 months ago

009420.KQ

009420.KS
+3.01%
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates.

PR Newswire 5 months ago

009420.KQ

009420.KS
+3.01%
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter of 2024 and provided business updates.

PR Newswire 8 months ago

009420.KQ

009420.KS
+3.01%
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christopher W. Slavinsky as Chief Business Development and Legal Officer.

PR Newswire 8 months ago

009420.KQ

009420.KS
+3.01%
Turn Bio and HanAll to develop therapies for age-related conditions

HanAll's initial investment in Turn Bio in 2022 laid the groundwork for this expanded collaboration.

Pharmaceutical Technology 10 months ago

009420.KS
+3.01%
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.

PR Newswire 10 months ago

009420.KS
+3.01%
HanAll Biopharma initiates Phase III DED treatment trial

The trial will assess the efficacy and safety of tanfanercept ophthalmic solution given twice daily.

Clinical Trials Arena 10 months ago

009420.KS
+3.01%
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced the initiation of a Phase III VELOS-4 trial evaluating the efficacy and safety of tanfanercept, a novel, topical anti-inflammatory treatment in participants with moderate to severe dry eye disease (DED).

PR Newswire 11 months ago

009420.KS
+3.01%
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for first quarter 2024 and provided business updates.

PR Newswire 11 months ago

009420.KS
+3.01%

Performance Overview

Return	009420.KS	KOSPI Composite Index (^KS11)
YTD	-29.11%	+1.38%
1-Year	-13.84%	-10.13%
3-Year	+47.31%	-9.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hanall Biopharma Co., Ltd. (009420.KS)

HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Turn Bio and HanAll to develop therapies for age-related conditions

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

HanAll Biopharma initiates Phase III DED treatment trial

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update

Performance Overview